Sartorius pledges to cut development times with upstream suite

By Phil Taylor

- Last updated on GMT

iStock/ktsimage
iStock/ktsimage

Related tags: Gene expression, Cell culture, Chinese hamster ovary cell

Sartorius Stedim Biotech claims it has a platform that can help biopharma companies carve months off the development time for new products.

The Franco-German company has bundled all its upstream bioprocessing products and services into a single platform - dubbed Connect Upstream - that it says can help biopharma companies go from concept to clinic in a little over a year.

It is pitching the system particularly at companies developing biosimilars as a means to reduce the time to market and cut productions costs, taking projects from cell line development through to 2,000-litre commercial manufacturing.

Biopharma companies often face significant challenges scaling up their processes so they are robust, comply with regulations and which deliver high titres that can keep cost of goods down, according to the company.

The new platform relies heavily on disposable technologies​ and also draws upon Sartorius Stedim's proprietary Cellca​ Chinese hamster ovary (CHO) cell expression system, Ambr cell-line selection system and 100-plus range of BioOutsource​ pre-qualified biosimilar assays.

The Cellca and BioOutsource products were acquired by the company last year and have helped drive a 22% increase in revenues​ at the company in the first half of the year.

Sartorius Stedim's growth is being driven by the increasing proportion of global drug market sales accounted for by biological products. This has nearly doubled over the last ten years, recently reaching just under a quarter of the total market, according to IMS Health data.

Time to clinic is particularly important, according to Miriam Monge, Sartorius Stedim's director of integrated solutions." Due to growing pipelines, efficiencies must be gained in process development [but] in the past cell line and process development has been slow and labour-intensive," she said.

Sartorius Stedim's system "now means that starting with a gene you can have a robust, high-titre cell line, upstream process and fully characterised product within 14 months​."

Related news

Show more

Related products

show more

Manufacturing of hiPSC-Derived Cardiomyocytes

Manufacturing of hiPSC-Derived Cardiomyocytes

Eppendorf for Bioprocess – Solutions that grow with you | 29-Oct-2020 | Application Note

Effective drug discovery and development relies on the availability of predictive preclinical model systems. Technologies based on human induced pluripotent...

Related suppliers

Follow us

Products

View more

Webinars